134 related articles for article (PubMed ID: 10416839)
1. Two non-reactive ternary complexes of estrogenic 17beta-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis.
Qiu W; Zhu DW; Azzi A; Campbell RL; Qi H; Poirier D; Lin SX
J Steroid Biochem Mol Biol; 1999 Mar; 68(5-6):239-44. PubMed ID: 10416839
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of human 17β-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP
Li T; Stephen P; Zhu DW; Shi R; Lin SX
FEBS J; 2019 Jun; 286(11):2155-2166. PubMed ID: 30768851
[TBL] [Abstract][Full Text] [Related]
3. Crystallization and preliminary crystal structure of the complex of 17beta-hydroxysteroid dehydrogenase with a dual-site inhibitor.
Zhu DW; Campbell R; Labrie F; Lin SX
J Steroid Biochem Mol Biol; 1999; 70(4-6):229-35. PubMed ID: 10622412
[TBL] [Abstract][Full Text] [Related]
4. 3D-structure of human estrogenic 17beta-HSD1: binding with various steroids.
Lin SX; Han Q; Azzi A; Zhu DW; Gangloff A; Campbell RL
J Steroid Biochem Mol Biol; 1999; 69(1-6):425-9. PubMed ID: 10419021
[TBL] [Abstract][Full Text] [Related]
5. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.
Breton R; Housset D; Mazza C; Fontecilla-Camps JC
Structure; 1996 Aug; 4(8):905-15. PubMed ID: 8805577
[TBL] [Abstract][Full Text] [Related]
6. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
[TBL] [Abstract][Full Text] [Related]
7. Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.
Sawicki MW; Erman M; Puranen T; Vihko P; Ghosh D
Proc Natl Acad Sci U S A; 1999 Feb; 96(3):840-5. PubMed ID: 9927655
[TBL] [Abstract][Full Text] [Related]
8. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
[TBL] [Abstract][Full Text] [Related]
9. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
10. Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase.
Mazza C; Breton R; Housset D; Fontecilla-Camps JC
J Biol Chem; 1998 Apr; 273(14):8145-52. PubMed ID: 9525918
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
13. Purification, crystallization and preliminary X-ray diffraction results of human 17beta-hydroxysteroid dehydrogenase type 5.
Zhou M; Qiu W; Chang HJ; Gangloff A; Lin SX
Acta Crystallogr D Biol Crystallogr; 2002 Jun; 58(Pt 6 Pt 2):1048-50. PubMed ID: 12037313
[TBL] [Abstract][Full Text] [Related]
14. Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation.
Negri M; Recanatini M; Hartmann RW
PLoS One; 2010 Aug; 5(8):e12026. PubMed ID: 20706575
[TBL] [Abstract][Full Text] [Related]
15. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
16. Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation.
Shi R; Lin SX
J Biol Chem; 2004 Apr; 279(16):16778-85. PubMed ID: 14966133
[TBL] [Abstract][Full Text] [Related]
17. New insights into the substrate inhibition of human 17β-hydroxysteroid dehydrogenase type 1.
Li T; Song X; Stephen P; Yin H; Lin SX
J Steroid Biochem Mol Biol; 2023 Apr; 228():106246. PubMed ID: 36634828
[TBL] [Abstract][Full Text] [Related]
18. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
[TBL] [Abstract][Full Text] [Related]
19. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
[TBL] [Abstract][Full Text] [Related]
20. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Tremblay MR; Poirier D
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
